DG031: Phase IIa data

In a double-blind, placebo-controlled, dose-ranging, Icelandic Phase IIa trial in 172 patients, DG031 suppressed production of three biomarkers, leukotriene B4 (LTB4), myeloperoxidase (MPO) and sICA...